<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200697">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477425</url>
  </required_header>
  <id_info>
    <org_study_id>AVF4223g</org_study_id>
    <nct_id>NCT00477425</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab</brief_title>
  <official_title>Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval
      in cancer patients. Patients who have consented to participate in selected randomized
      controlled bevacizumab clinical trials will be invited to participate in this study.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2007</start_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>150</enrollment>
  <condition>Carcinoma</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Enrollment in one of a list of certain randomized, controlled bevacizumab trials

        Exclusion Criteria:

          -  Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)

          -  Congenital long QT syndrome

          -  Family history of long QT syndrome

          -  Clinically significant bradycardia (defined as &lt; 50 beats/minute)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Huang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <verification_date>December 2010</verification_date>
  <lastchanged_date>December 1, 2010</lastchanged_date>
  <firstreceived_date>May 21, 2007</firstreceived_date>
  <keyword>Avastin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
